Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wesley T Beaulieu

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Nature Communications|February 20, 2014
Bending rules for animal propulsionKelsey N Lucas, Nathan Johnson, Wesley T Beaulieu, et al.
Ophthalmology|August 11, 2018
Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic RetinopathyJennifer K Sun, Adam R Glassman, Wesley T Beaulieu, et al.
Clinical Trials (London, England)|January 28, 2020
Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trialAdam R Glassman, Wesley T Beaulieu, Cynthia R Stockdale, et al.
JAMA Ophthalmology|May 6, 2021
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Wesley T Beaulieu, Maureen G Maguire, et al.
JAMA Ophthalmology|February 21, 2020
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Carl W Baker, Wesley T Beaulieu, et al.
Ophthalmology|May 14, 2020
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)Adam R Glassman, John A Wells, Kristin Josic, et al.
Retina (Philadelphia, Pa.)|October 1, 2019
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical TrialsNeil M Bressler, Wesley T Beaulieu, Susan B Bressler, et al.
American Journal of Ophthalmology|August 6, 2018
Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol TNeil M Bressler, Wesley T Beaulieu, Maureen G Maguire, et al.
Neural Regeneration Research|November 25, 2017
Locomotor analysis identifies early compensatory changes during disease progression and subgroup classification in a mouse model of amyotrophic lateral sclerosisMelissa M Haulcomb, Rena M Meadows, Whitney M Miller, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|July 30, 2025
Ophthalmic outcomes five years after lensectomy among children with Down syndromeAlejandra G de Alba Campomanes, Michael X Repka, Rui Wu, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Nature Communications|February 20, 2014
Bending rules for animal propulsionKelsey N Lucas, Nathan Johnson, Wesley T Beaulieu, et al.
Ophthalmology|August 11, 2018
Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic RetinopathyJennifer K Sun, Adam R Glassman, Wesley T Beaulieu, et al.
Clinical Trials (London, England)|January 28, 2020
Effect of telephone calls from a centralized coordinating center on participant retention in a randomized clinical trialAdam R Glassman, Wesley T Beaulieu, Cynthia R Stockdale, et al.
JAMA Ophthalmology|May 6, 2021
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Wesley T Beaulieu, Maureen G Maguire, et al.
JAMA Ophthalmology|February 21, 2020
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical TrialAdam R Glassman, Carl W Baker, Wesley T Beaulieu, et al.
Ophthalmology|May 14, 2020
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)Adam R Glassman, John A Wells, Kristin Josic, et al.
Retina (Philadelphia, Pa.)|October 1, 2019
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical TrialsNeil M Bressler, Wesley T Beaulieu, Susan B Bressler, et al.
American Journal of Ophthalmology|August 6, 2018
Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol TNeil M Bressler, Wesley T Beaulieu, Maureen G Maguire, et al.
Neural Regeneration Research|November 25, 2017
Locomotor analysis identifies early compensatory changes during disease progression and subgroup classification in a mouse model of amyotrophic lateral sclerosisMelissa M Haulcomb, Rena M Meadows, Whitney M Miller, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|July 30, 2025
Ophthalmic outcomes five years after lensectomy among children with Down syndromeAlejandra G de Alba Campomanes, Michael X Repka, Rui Wu, et al.
Pageof 5